Ignite Creation Date:
2024-05-06 @ 1:13 PM
Last Modification Date:
2024-10-26 @ 1:10 PM
Study NCT ID:
NCT03964233
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-09
First Post:
2019-05-24
Brief Title:
A Study in Patients With Different Types of Advanced Cancer Solid Tumors to Test Different Doses of BI 907828 Brigimadlin in Combination With BI 754091 Ezabenlimab and BI 754111 or BI 907828 Brigimadlin in Combination With BI 754091 Ezabenlimab
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Organization Data
Organization:
Boehringer Ingelheim
Class:
INDUSTRY
Study ID:
1403-0002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Boehringer Ingelheim
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None